New Retina Radio by Eyetube

How should retina specialists integrate next-generation anti-VEGFs into everyday wet AMD care? In this episode of “Anti-VEGFs: The Next Generation,” David Miller, MD, speaks with Esther Kim, MD, and Ehsan Rahimy, MD, about real-world issues facing wet AMD care, such as navigating crowded drug fridges, attempting interval extensions, and switching from legacy agents to next-generations treatments.  This editorially independent series is supported with advertising by Regeneron.

How should retina specialists integrate next-generation anti-VEGF agents into real-world DME care? In this episode of “Anti-VEGFs: The Next Generation,” David Miller, MD, speaks with Esther Kim, MD, and Ehsan Rahimy, MD, about first-line agent selection, when to transition to newer options, how to incorporate steroids thoughtfully, and crafting dosing strategies that balance durability, efficacy, and adherence for working-age patients—without overpromising outcomes.This editorially independent series is supported with advertising by Regeneron.

Can smarter strategies to tame retinal fluid fluctuations actually improve long-term vision? In episode 3 of this miniseries, host Jay Sridhar, MD, and panelists Durga Borkar, MD, MMCi, and Christina Weng, MD, MBA, examine the data linking sustained delivery of therapy, reductions in retinal thickness changes, and positive long-term vision outcomes. After the break, the trio looks ahead to sustained TKI therapy via EYP-1901 (Duravyu, EyePoint Pharmaceuticals) by examining data from the DAVIO-2 study. Drs. Sridhar, Borkar, and Weng are paid consultants of EyePoint Pharmaceuticals; however, the statements made are the opinions of Drs. Sridhar, Borkar, and Weng for educational purposes only; their statements are not intended as medical advice or the opinion of EyePoint.

Do retinal fluid fluctuations quietly erode long-term vision? In episode 2 of a 3-part roundtable series, moderator Jay Sridhar, MD joins guests Maggie Runner, MD, and Veeral Sheth, MD, MBA, to translate key data into clinic-ready tactics. They unpack how volatility—not just volume—of fluid correlates with outcomes, which fluid compartments matter most, and why durability reduces “yo-yo” anatomy. Drs. Sridhar, Runner, and Sheth are paid consultants of EyePoint Pharmaceuticals; however, the statements made are the opinions of Drs. Sridhar, Runner, and Sheth for educational purposes only; their statements are not intended as medical advice or the opinion of EyePoint.

In this first episode of a 3-part roundtable series, moderator Jay Sridhar, MD, speaks with David Sarraf, MD, and Danny Mammo, MD, about retinal fluid fluctuation as a modifiable driver of outcomes in neovascular AMD and DME. The panel defines fluctuation across compartments, examines practical barriers to longitudinal OCT tracking, and assesses the undertreatment gap in real-world practice.  Drs. Sridhar, Mammo, and Sarraf are paid consultants of EyePoint Pharmaceuticals; however, the statements made are the opinions of Drs. Sridhar, Mammo, and Sarraf for educational purposes only; their statements are not intended as medical advice or the opinion of EyePoint.